Solid Tumors, Adult

Oncology
5
Pipeline Programs
4
Companies
5
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

H
HutchmedChina - Hong Kong
2 programs
2
HMPL-A251Phase 1/21 trial
HMPL-A580Phase 1/21 trial
Active Trials
NCT07228247Recruiting147Est. Dec 2028
NCT07396584Not Yet Recruiting186Est. Jan 2029
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
1
DCR-PDL1Phase 11 trial
Active Trials
NCT06504368Recruiting32Est. Dec 2027
Jacobio Pharmaceuticals
1 program
1
JAB-8263Phase 11 trial
Active Trials
NCT04587479CompletedEst. Oct 2024
Virtuoso Therapeutics
Virtuoso TherapeuticsCA - San Mateo
1 program
1
VP301Phase 11 trial
Active Trials
NCT05698888Terminated2Est. Jun 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
HutchmedHMPL-A580
HutchmedHMPL-A251
Novo NordiskDCR-PDL1
Virtuoso TherapeuticsVP301
Jacobio PharmaceuticalsJAB-8263

Clinical Trials (5)

Total enrollment: 367 patients across 5 trials

NCT07396584HutchmedHMPL-A580

A Phase I/Ⅱa Study of HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor

Start: Mar 2026Est. completion: Jan 2029186 patients
Phase 1/2Not Yet Recruiting
NCT07228247HutchmedHMPL-A251

A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors

Start: Dec 2025Est. completion: Dec 2028147 patients
Phase 1/2Recruiting
NCT06504368Novo NordiskDCR-PDL1

Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors

Start: May 2024Est. completion: Dec 202732 patients
Phase 1Recruiting
NCT05698888Virtuoso TherapeuticsVP301

Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors

Start: Nov 2022Est. completion: Jun 20232 patients
Phase 1Terminated
NCT04587479Jacobio PharmaceuticalsJAB-8263

A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors

Start: Nov 2020Est. completion: Oct 2024
Phase 1Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
16m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
16m ago

Office Administrator

SystImmune
16m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
26m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
30m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
30m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 367 patients
4 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)